EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitMultizentrische StudieOpen Access · CC BY 4.0

Anti‐TNF Drug‐Induced Sarcoidosis in Inflammatory Bowel Diseases: Multicentric Case Series and Literature Review

Patrick Bez, Zlata Chkolnaia iD, Annalisa Aratari iD, Marta Ascolani, Péter Bacsur iD, Andreas Blesl, Philippe Seksik, Sara Nikolic, Savarino Edoardo V iD, Marcello Rattazzi, Francesco Cinetto, Carla Felice iD

BioMed Research International · 2026-01 · 2026 (1)

DOI: 10.1155/bmri/7554982 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioMed Research International, online erschienen am 22.05.2026. Verfasst von Patrick Bez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Rare Diseases Referral Center, Internal Medicine 1, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Treviso, Italy. Hauptthemen laut MEDLINE: Sarcoidosis, Tumor Necrosis Factor-alpha, Inflammatory Bowel Diseases. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universita degli Studi di Padova, CRUI-CARE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sarcoidosis is an inflammatory granulomatous condition and presents overlapping features with inflammatory bowel disease (IBD). Anti‐TNF treatment has revolutionized the management of several conditions, including IBD and sarcoidosis. Yet, anti‐TNF drugs have been associated with drug‐induced sarcoidosis reaction (DISR).

Methods

This is a retrospective, international, multicentric case series, including IBD patients with anti‐TNF–related DISR. A literature review was performed to identify previously published cases.

Results

Nine new cases of anti‐TNF–related DISR in IBD are described with a long follow‐up (median 45 months). After literature review, a total of 26 cases were identified. The diagnosis required histological evidence of granulomas in involved organs in all patients. Most patients had a diagnosis of Crohn′s disease ( n = 19, 73.1%). The culprit drug was infliximab in 15 (57.7%) and adalimumab in 11 (42.3%). The median time to sarcoidosis development was 21 months. Compared to conventional sarcoidosis, extrathoracic involvement was more prevalent ( n = 20, 76.7%). Management of DISR consisted of discontinuing anti‐TNF treatment in 20 cases (76.9%) and providing specific treatment in 17 cases (65.4%), with favorable outcomes in all cases.

Conclusion

Despite its rarity, DISR may be challenging for IBD patients. Discontinuation of anti‐TNF treatment is recommended, and specific treatment is required for moderate‐to‐severe cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcoidosisTumor Necrosis Factor-alphaInflammatory Bowel DiseasesHumansFemaleAdultInfliximabMaleAdalimumabMiddle AgedRetrospective Studies

Stichwörter der Autor:innen

anti-TNFdrug-induced sarcoidosisinflammatory bowel diseaseinfliximabsarcoidosis

Substanzen

InfliximabTumor Necrosis Factor-alphaAdalimumab

Autor:innen und Institutionen

  • Rare Diseases Referral Center, Internal Medicine 1, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Treviso, Italy.
  • Gastroenterology Department, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP Saint-Antoine Hospital, Paris, France, sorbonne-universites.fr.
  • IBD UNIT, San Filippo Neri Hospital, Rome, Italy, sanfilipponeri.roma.it.
  • Gastroenterology Unit, Ca' Foncello University Hospital, Treviso, Italy.
  • Center for Gastroenterology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary, u-szeged.hu.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria, medunigraz.at.

ORCID-Profile: Zlata Chkolnaia, Annalisa Aratari, Péter Bacsur, Savarino Edoardo V, Carla Felice

Förderung

  • Universita degli Studi di Padova
  • CRUI-CARE

Zitieren

APA

Bez, P., Chkolnaia, Z., Aratari, A., Ascolani, M., Bacsur, P., Blesl, A., Seksik, P., Nikolic, S., Edoardo V, S., Rattazzi, M., Cinetto, F., & Felice, C. (2026). Anti‐TNF Drug‐Induced Sarcoidosis in Inflammatory Bowel Diseases: Multicentric Case Series and Literature Review. BioMed Research International, 2026(1). https://doi.org/10.1155/bmri/7554982

Vancouver

Bez P, Chkolnaia Z, Aratari A, Ascolani M, Bacsur P, Blesl A, et al. Anti‐TNF Drug‐Induced Sarcoidosis in Inflammatory Bowel Diseases: Multicentric Case Series and Literature Review. BioMed Research International. 2026;2026(1). doi:10.1155/bmri/7554982

BibTeX
@article{Bez2026,
  author = {Bez, Patrick and Chkolnaia, Zlata and Aratari, Annalisa and Ascolani, Marta and Bacsur, Péter and Blesl, Andreas and Seksik, Philippe and Nikolic, Sara and Edoardo V, Savarino and Rattazzi, Marcello and Cinetto, Francesco and Felice, Carla},
  title = {Anti‐TNF Drug‐Induced Sarcoidosis in Inflammatory Bowel Diseases: Multicentric Case Series and Literature Review},
  journal = {BioMed Research International},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/bmri/7554982}
}
Kostenlos starten →